A Phase 3 Open-label Rollover Clinical Study of | Clinical Research Studies Listing

Recruiting

99 years or below

All

1 Location

Brief description of study

This trial is testing doravirine/islatravir (also known as MK-8591A or DOR/ISL) in people living with HIV-1 who have participated in another Merck-sponsored trial of DOR/ISL. The main purpose of this trial is to test the safety and efficacy of DOR/ISL and give patients continued access to DOR/ISL through this rollover study. Participants will take DOR/ISL for an additional 48 weeks or until DOR/ISL is commercially available and come in for routine study visits every 3 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 10 May 2023. Study ID: 851182

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in subjects Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Brief description of study

Eligibility of study

Find a site

Interested in the study